Sequoia China co-leads $25m Series B in US biotech firm Refuge

Retrieved on: 2018-05-01 15:07:30

Tags for this article:

Sequoia Capital China

Cancer immunotherapy

Click the tags to see associated articles and topics

Sequoia China co-leads $25m Series B in US biotech firm Refuge. View article details on hiswai:

Excerpt

<div>Venture capital firm <b>Sequoia Capital</b> China has co-led a $25-million Series B funding round in Refuge Biotechnologies, a California-based biotech startup that leverages gene engineering technologies to develop therapeutic cells that fight cancer. Sequoia China joins 3SBio, a biotechnology company in ...</div>

Article found on:

View Original Article